688098 申联生物
已收盘 12-26 15:00:01
资讯
新帖
简况
申联生物（688098）披露股东一致行动关系终止暨权益变动触及5%整数倍的提示性公告，12月22日股价上涨1.22%
证券之星 · 12-22
申联生物（688098）披露股东一致行动关系终止暨权益变动触及5%整数倍的提示性公告，12月22日股价上涨1.22%
申联生物(688098.SH)联营公司世之源获艾滋病单抗发明专利
智通财经网 · 12-19
申联生物(688098.SH)联营公司世之源获艾滋病单抗发明专利
12月19日申联生物发生1笔大宗交易 成交金额1806.64万元
证券之星 · 12-19
12月19日申联生物发生1笔大宗交易 成交金额1806.64万元
申联生物（688098）披露持股5%以上股东权益变动触及5%整数倍的提示性公告，11月28日股价下跌0.41%
中金财经 · 11-29
申联生物（688098）披露持股5%以上股东权益变动触及5%整数倍的提示性公告，11月28日股价下跌0.41%
11月28日申联生物发布公告，股东减持213.54万股
证券之星 · 11-28
11月28日申联生物发布公告，股东减持213.54万股
每周股票复盘：申联生物（688098）将召开2025年Q3业绩说明会
证券之星 · 11-16
每周股票复盘：申联生物（688098）将召开2025年Q3业绩说明会
申联生物（688098）披露召开2025年第三季度业绩说明会的公告，11月13日股价上涨1.51%
证券之星 · 11-13
申联生物（688098）披露召开2025年第三季度业绩说明会的公告，11月13日股价上涨1.51%
每周股票复盘：申联生物（688098）拟年内完成对世之源增资至51%
证券之星 · 11-09
每周股票复盘：申联生物（688098）拟年内完成对世之源增资至51%
申联生物：10月31日接受机构调研，中信菱信、中信证券农业等多家机构参与
证券之星 · 11-04
申联生物：10月31日接受机构调研，中信菱信、中信证券农业等多家机构参与
每周股票复盘：申联生物（688098）Q3净利降35.50%
证券之星 · 11-02
每周股票复盘：申联生物（688098）Q3净利降35.50%
申联生物（688098）2025年三季报简析：净利润同比增长101.97%，公司应收账款体量较大
证券之星 · 10-28
申联生物（688098）2025年三季报简析：净利润同比增长101.97%，公司应收账款体量较大
申联生物最新公告：拟收购联营公司世之源控股权并签署收购框架协议
证券之星 · 10-26
申联生物最新公告：拟收购联营公司世之源控股权并签署收购框架协议
申联生物(688098)9月30日股东户数1.24万户，较上期增加30.87%
证券之星 · 10-26
申联生物(688098)9月30日股东户数1.24万户，较上期增加30.87%
申联生物(688098.SH)发布前三季度业绩，归母净利润28万元，同比扭亏为盈
智通财经 · 10-26
申联生物(688098.SH)发布前三季度业绩，归母净利润28万元，同比扭亏为盈
每周股票复盘：UBI拟减持申联生物（688098）不超3%股份
证券之星 · 10-26
每周股票复盘：UBI拟减持申联生物（688098）不超3%股份
申联生物（688098）披露持股5%以上股东减持股份计划公告，10月22日股价下跌0.82%
证券之星 · 10-22
申联生物（688098）披露持股5%以上股东减持股份计划公告，10月22日股价下跌0.82%
申联生物(688098.SH)：UBI拟减持不超3%股份
智通财经 · 10-22
申联生物(688098.SH)：UBI拟减持不超3%股份
申联生物称股东计划在2026年2月12日前减持最高3%股份
美股速递 · 10-22
申联生物称股东计划在2026年2月12日前减持最高3%股份
股市必读：申联生物（688098）9月17日披露最新机构调研信息
证券之星 · 09-18
股市必读：申联生物（688098）9月17日披露最新机构调研信息
每周股票复盘：申联生物（688098）获批新兽药文号
证券之星 · 09-14
每周股票复盘：申联生物（688098）获批新兽药文号
加载更多
公司概况
公司名称：
申联生物医药(上海)股份有限公司
所属行业：
医药制造业
上市日期：
2019-10-28
主营业务：
申联生物医药(上海)股份有限公司的主营业务是涵盖动物预防、治疗及诊断生物产品的研发、生产和销售。公司的主要产品是系列猪、牛羊口蹄疫疫苗、猪圆环病毒2型亚单位疫苗、牛结节性皮肤病灭活疫苗及系列兽医诊断制品。公司于2024年荣获第七届中国(上海)国际发明创新展览会金奖2项。
发行价格：
8.80
{"stockData":{"symbol":"688098","market":"SH","secType":"STK","nameCN":"申联生物","latestPrice":8.91,"timestamp":1766732401000,"preClose":8.97,"halted":0,"volume":2807565,"delay":0,"changeRate":-0.0067,"floatShares":411000000,"shares":411000000,"eps":-0.0739,"marketStatus":"已收盘","change":-0.06,"latestTime":"12-26 15:00:01","open":9,"high":9.03,"low":8.86,"amount":25113900,"amplitude":0.019,"askPrice":8.92,"askSize":273,"bidPrice":8.91,"bidSize":1,"shortable":0,"etf":0,"ttmEps":-0.0739,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766971800000},"marketStatusCode":5,"adr":0,"adjPreClose":8.97,"symbolType":"stock_kcb","openAndCloseTimeList":[[1766712600000,1766719800000],[1766725200000,1766732400000]],"highLimit":9.87,"lowLimit":8.07,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":410644000,"isCdr":false,"pbRate":2.6,"roa":"--","roe":"0.02%","epsLYR":-0.11,"committee":-0.207188,"marketValue":3659000000,"turnoverRate":0.0068,"status":1,"afterMarket":{"amount":0,"volume":0,"close":8.91,"buyVolume":0,"sellVolume":0,"time":1766734437768,"indexStatus":"已收盘 12-26 15:30:00","preClose":8.97},"floatMarketCap":3659000000},"requestUrl":"/m/hq/s/688098","defaultTab":"news","newsList":[{"id":"2593485213","title":"申联生物（688098）披露股东一致行动关系终止暨权益变动触及5%整数倍的提示性公告，12月22日股价上涨1.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593485213","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593485213?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:52","pubTimestamp":1766397174,"startTime":"0","endTime":"0","summary":"截至2025年12月22日收盘，申联生物报收于9.12元，较前一交易日上涨1.22%，最新总市值为37.45亿元。近日，申联生物发布关于股东一致行动关系终止暨权益变动触及5%整数倍的提示性公告。本次变动后，上述自然人股东合计持股比例由35.82%降至30.78%，触及5%整数倍权益变动披露标准。公告指出，各股东持股数量未发生变化，本次变动不触及要约收购，公司控制权未发生变更。此外，申太联将遵守相关减持规定，在六个月内不减持其所持股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200022571.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"gpt_icon":0},{"id":"2592616012","title":"申联生物(688098.SH)联营公司世之源获艾滋病单抗发明专利","url":"https://stock-news.laohu8.com/highlight/detail?id=2592616012","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592616012?lang=zh_cn&edition=full","pubTime":"2025-12-19 22:18","pubTimestamp":1766153894,"startTime":"0","endTime":"0","summary":"智通财经APP讯，申联生物 公告，公司联营公司扬州世之源生物科技有限责任公司于近日获得国家知识产权局颁发的“借由针对CD4之单克隆抗体介导竞争型HIV进入抑制之HIV感染的治疗和功能性治愈”的发明专利，此发明专利是关于针对CD4单克隆抗体、其组合物以及使用此组合物以预防、治疗和功能性治愈HIV感染的方法。因UB-421并非直接针对病毒基因，所以相较于当前市场上现有的治疗艾滋病药物，UB-421引起病毒耐药突变的概率较低，且具有免疫调节作用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384013.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"申联生物(688098.SH)联营公司世之源获艾滋病单抗发明专利","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["688098","BK0239"],"gpt_icon":0},{"id":"2592150058","title":"12月19日申联生物发生1笔大宗交易 成交金额1806.64万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2592150058","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592150058?lang=zh_cn&edition=full","pubTime":"2025-12-19 17:47","pubTimestamp":1766137674,"startTime":"0","endTime":"0","summary":"证券之星消息，12月19日申联生物发生大宗交易，交易数据如下：大宗交易成交价格8.8元，相对当日收盘价折价2.33%，成交205.3万股，成交金额1806.64万元，买方营业部为中信建投证券股份有限公司广西分公司，卖方营业部为国信证券股份有限公司上海陆家嘴环路证券营业部。近三个月该股共发生1笔大宗交易，合计成交2.05万手，折价成交1笔。截至2025年12月19日收盘，申联生物报收于9.01元，上涨2.15%，换手率0.63%，成交量2.57万手，成交额2306.3万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900027352.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"gpt_icon":0},{"id":"2587975376","title":"申联生物（688098）披露持股5%以上股东权益变动触及5%整数倍的提示性公告，11月28日股价下跌0.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2587975376","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2587975376?lang=zh_cn&edition=full","pubTime":"2025-11-29 08:14","pubTimestamp":1764375281,"startTime":"0","endTime":"0","summary":"近日，申联生物发布关于持股5%以上股东权益变动触及5%整数倍的提示性公告。公告显示，公司持股5%以上股东美国联合生物医药公司通过大宗交易方式减持股份，持股比例由10.52%减少至10.00%，合计持股降至4106.4498万股，触及5%整数倍。本次权益变动未导致公司控股股东、实际控制人变化，不触发强制要约收购义务。信息披露义务人已编制简式权益变动报告书并披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251129/31833244.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688098","BK0239"],"gpt_icon":0},{"id":"2586786202","title":"11月28日申联生物发布公告，股东减持213.54万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2586786202","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586786202?lang=zh_cn&edition=full","pubTime":"2025-11-28 19:01","pubTimestamp":1764327693,"startTime":"0","endTime":"0","summary":"证券之星消息，11月28日申联生物发布公告《申联生物:申联生物医药(上海)股份有限公司简式权益变动报告书》，其股东UNITED BIOMEDICAL,INC.于2025年11月24日至2025年11月28日间合计减持213.54万股，占公司目前总股本的0.52%，变动期间该股股价上涨3.11%，截止11月28日收盘报9.62元。股东增减持详情见下表：根据申联生物2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800030045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"gpt_icon":0},{"id":"2583825651","title":"每周股票复盘：申联生物（688098）将召开2025年Q3业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2583825651","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583825651?lang=zh_cn&edition=full","pubTime":"2025-11-16 03:14","pubTimestamp":1763234054,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，申联生物报收于10.61元，较上周的10.81元下跌1.85%。本周，申联生物11月14日盘中最高价报10.86元。11月13日盘中最低价报10.45元。申联生物当前最新总市值43.57亿元，在动物保健板块市值排名10/11，在两市A股市值排名3750/5165。投资者可在2025年11月24日至11月28日16:00前通过上证路演中心网站或公司邮箱slsw@slbio.com.cn提交问题。公司董事长聂东升、董事会秘书于海霞、技术总监殷波博士、财务总监李珣将出席。说明会后内容可通过上证路演中心查看。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"gpt_icon":0},{"id":"2583359187","title":"申联生物（688098）披露召开2025年第三季度业绩说明会的公告，11月13日股价上涨1.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583359187","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583359187?lang=zh_cn&edition=full","pubTime":"2025-11-13 22:53","pubTimestamp":1763045592,"startTime":"0","endTime":"0","summary":"截至2025年11月13日收盘，申联生物报收于10.76元，较前一交易日上涨1.51%，最新总市值为44.19亿元。公司近日发布公告称，申联生物医药(上海)股份有限公司将于2025年12月1日16:00-17:00通过上海证券交易所上证路演中心举行2025年第三季度业绩说明会，以网络文字互动形式与投资者交流公司经营成果、财务状况及创新药业务进展。投资者可于2025年11月24日至11月28日16:00前通过上证路演中心网站或公司邮箱slsw@slbio.com.cn提交问题。说明会后可通过上证路演中心查看会议内容。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300042796.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"gpt_icon":0},{"id":"2582086433","title":"每周股票复盘：申联生物（688098）拟年内完成对世之源增资至51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582086433","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582086433?lang=zh_cn&edition=full","pubTime":"2025-11-09 04:44","pubTimestamp":1762634652,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，申联生物报收于10.81元，较上周的11.2元下跌3.48%。本周关注点来自机构调研要点：申联生物力争年内完成对世之源增资，实现持股比例提升至51%。答：公司正按计划积极推进收购世之源事项，力争于本年度内完成此次增资，以实现持股比例提升至51%之目标。在实现控股后，申联生物能更有效地推动世之源后续产品的商业化进程，为所有股东创造更大价值。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001694.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"gpt_icon":0},{"id":"2580276802","title":"申联生物：10月31日接受机构调研，中信菱信、中信证券农业等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2580276802","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580276802?lang=zh_cn&edition=full","pubTime":"2025-11-04 09:34","pubTimestamp":1762220073,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年11月3日申联生物发布公告称公司于2025年10月31日接受机构调研，中信菱信姚宏福、中信证券农业施扬、中信保诚基金高岳昂、上银基金纪晓天、国海富兰克林刘牧、银华基金吴颖、中金公司杨钟男、长江证券医药刘长洪、国投证券医药谢嘉豪、华创证券医药吴昱爽参与。目前已签署的协议虽为框架性协议,但交易的核心条款已与相关方达成实质性共识。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400007871.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1147","LU1064130708.USD","600030","LU2148510915.USD","LU1997245177.USD","LU0405327148.USD","BK0276","BK1564","LU0405327494.USD","BK0196","BK0239","LU1997245094.SGD","LU1997244956.HKD","LU2289578879.USD","LU1255011170.USD","BK0028","BK0012","688098","LU1064131003.USD","BK0188","06030","LU1655091616.SGD","BK1516","LU2495084118.USD","LU1328615791.USD","BK1521","LU1720050803.USD","LU1794554557.SGD","BK0183"],"gpt_icon":0},{"id":"2580403317","title":"每周股票复盘：申联生物（688098）Q3净利降35.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580403317","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580403317?lang=zh_cn&edition=full","pubTime":"2025-11-02 09:24","pubTimestamp":1762046654,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，申联生物报收于11.2元，较上周的10.75元上涨4.19%。本周，申联生物10月27日盘中最高价报12.2元。申联生物当前最新总市值45.99亿元，在动物保健板块市值排名7/11，在两市A股市值排名3531/5163。本周关注点来自业绩披露要点：申联生物2025年第三季度单季净利润同比下降35.50%。公司公告汇总申联生物全资子公司本天成持有联营公司世之源20.48%股权。交易完成后，申联生物及其一致行动人合计持股不低于51%，实现对世之源实质控制。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200002077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"gpt_icon":0},{"id":"2578674558","title":"申联生物（688098）2025年三季报简析：净利润同比增长101.97%，公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2578674558","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578674558?lang=zh_cn&edition=full","pubTime":"2025-10-28 06:02","pubTimestamp":1761602549,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期申联生物发布2025年三季报。截至本报告期末，公司营业总收入2.38亿元，同比下降4.27%，归母净利润27.81万元，同比上升101.97%。按单季度数据看，第三季度营业总收入1.16亿元，同比下降4.89%，第三季度归母净利润1314.78万元，同比下降35.5%。本报告期申联生物公司应收账款体量较大，当期应收账款占最新年报营业总收入比达107.22%。此外，公司猪链球菌病、传染性胸膜肺炎二联灭活疫苗近期获准上市，预计今年也将贡献一定收入和利润。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800006295.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098"],"gpt_icon":0},{"id":"2578639584","title":"申联生物最新公告：拟收购联营公司世之源控股权并签署收购框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2578639584","media":"证券之星","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578639584?lang=zh_cn&edition=full","pubTime":"2025-10-26 17:19","pubTimestamp":1761470353,"startTime":"0","endTime":"0","summary":"申联生物(688098.SH)公告称，公司全资子公司本天成已完成对联营公司世之源的增资，并拟通过新一轮投资实现对世之源控股及实质控制。世之源将成为申联生物的控股孙公司，纳入上市公司合并报表范围。本次交易完成后，本天成与央扶基金各持有世之源16.99%的股权。此次收购构成关联交易，未构成重大资产重组。最终的收购方案需根据尽职调查及资产评估等情况进一步协商谈判，正式协议将提交公司董事会、股东会审议通过后生效。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600009983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"gpt_icon":0},{"id":"2578757636","title":"申联生物(688098)9月30日股东户数1.24万户，较上期增加30.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578757636","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578757636?lang=zh_cn&edition=full","pubTime":"2025-10-26 17:13","pubTimestamp":1761470022,"startTime":"0","endTime":"0","summary":"证券之星消息，近日申联生物披露，截至2025年9月30日公司股东户数为1.24万户，较6月30日增加2922.0户，增幅为30.87%。在动物保健行业个股中，申联生物股东户数低于行业平均水平，截至9月30日，动物保健行业平均股东户数为2.43万户。从股价来看，2025年6月30日至2025年9月30日，申联生物区间涨幅为73.32%，在此期间股东户数增加2922.0户，增幅为30.87%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600009461.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"gpt_icon":0},{"id":"2578721633","title":"申联生物(688098.SH)发布前三季度业绩，归母净利润28万元，同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2578721633","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578721633?lang=zh_cn&edition=full","pubTime":"2025-10-26 15:34","pubTimestamp":1761464067,"startTime":"0","endTime":"0","summary":"智通财经APP讯，申联生物(688098.SH)披露2025年第三季度报告，公司前三季度实现营收2.38亿元，同比下降4.27%;归母净利润28万元，同比扭亏为盈;扣非净利润亏损510万元;基本每股收益0元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1359908.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688098"],"gpt_icon":0},{"id":"2578502840","title":"每周股票复盘：UBI拟减持申联生物（688098）不超3%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2578502840","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578502840?lang=zh_cn&edition=full","pubTime":"2025-10-26 02:57","pubTimestamp":1761418629,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，申联生物报收于10.75元，较上周的11.43元下跌5.95%。本周关注点公司公告汇总：UBI计划减持申联生物不超过总股本3%的股份，用于支持创新药研发及基地建设。UBI非公司控股股东或实际控制人，本次减持不会导致公司控制权变更。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600000616.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"gpt_icon":0},{"id":"2577393777","title":"申联生物（688098）披露持股5%以上股东减持股份计划公告，10月22日股价下跌0.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577393777","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577393777?lang=zh_cn&edition=full","pubTime":"2025-10-22 22:23","pubTimestamp":1761142992,"startTime":"0","endTime":"0","summary":"截至2025年10月22日收盘，申联生物报收于10.93元，较前一交易日下跌0.82%，最新总市值为44.88亿元。该股当日开盘11.03元，最高11.62元，最低10.86元，成交额达1.46亿元，换手率为3.19%。近日，申联生物发布持股5%以上股东减持股份计划公告。公告强调，UBI非公司控股股东或实际控制人，本次减持不会导致公司控制权发生变更。减持期间，相关方将严格遵守法律法规要求，履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102200037600.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"gpt_icon":0},{"id":"2577365250","title":"申联生物(688098.SH)：UBI拟减持不超3%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2577365250","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577365250?lang=zh_cn&edition=full","pubTime":"2025-10-22 19:16","pubTimestamp":1761131788,"startTime":"0","endTime":"0","summary":"智通财经APP讯，申联生物(688098.SH)发布公告，美国联合生物医药公司(UNITED BIOMEDICAL, INC. 简称“UBI”)因推进其阿尔茨海默症合成肽疫苗等原研创新药的临床试验、商业化布局及与中国的合作伙伴加速与合成肽有关的生产制造基地的建设等而需资金投入，拟自公告披露之日起15个交易日之后的3个月内以通过上海证券交易所交易系统以集中竞价交易方式减持公司股份410.64万股，不超过公司股份总数的1%;以大宗交易方式减持公司股份821.29万股，不超过公司股份总数的2%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1358261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688098"],"gpt_icon":0},{"id":"1125454561","title":"申联生物称股东计划在2026年2月12日前减持最高3%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1125454561","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125454561?lang=zh_cn&edition=full","pubTime":"2025-10-22 18:40","pubTimestamp":1761129632,"startTime":"0","endTime":"0","summary":"申联生物称股东计划在2026年2月12日前减持最高3%股份，减持时间定于11月13日至2026年2月12日期间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688098","BK0239"],"gpt_icon":0},{"id":"2568415021","title":"股市必读：申联生物（688098）9月17日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2568415021","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568415021?lang=zh_cn&edition=full","pubTime":"2025-09-18 02:03","pubTimestamp":1758132198,"startTime":"0","endTime":"0","summary":"截至2025年9月17日收盘，申联生物报收于11.4元，下跌2.73%，换手率2.35%，成交量9.63万手，成交额1.11亿元。当日关注点来自交易信息汇总：9月17日主力资金净流出2008.6万元，占总成交额18.08%。猪链球菌病、传染性胸膜肺炎二联灭活疫苗近期获准上市，预计今年将贡献一定收入和利润。世之源将继续推进三款创新药研发并拓展新适应症，引入海外有竞争力管线，并结合申联生物的技术积累开展自主新药研发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091800001123.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"gpt_icon":0},{"id":"2567133001","title":"每周股票复盘：申联生物（688098）获批新兽药文号","url":"https://stock-news.laohu8.com/highlight/detail?id=2567133001","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567133001?lang=zh_cn&edition=full","pubTime":"2025-09-14 03:07","pubTimestamp":1757790432,"startTime":"0","endTime":"0","summary":"截至2025年9月12日收盘，申联生物报收于11.94元，较上周的11.76元上涨1.53%。本周，申联生物9月9日盘中最高价报12.4元。申联生物当前最新总市值48.66亿元，在动物保健板块市值排名7/11，在两市A股市值排名3385/5153。本周关注点公司公告汇总：申联生物获批猪链球菌病与传染性胸膜肺炎二联灭活疫苗兽药产品批准文号。产品已具备上市销售条件，上市前仅需履行批签发程序。新产品销售受防疫政策、市场容量、市场竞争等因素影响，收益存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091400000632.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766887129551,"stockEarnings":[{"period":"1week","weight":-0.0111},{"period":"1month","weight":-0.0767},{"period":"3month","weight":-0.1424},{"period":"6month","weight":0.4703},{"period":"1year","weight":0.6289},{"period":"ytd","weight":0.6289}],"compareEarnings":[{"period":"1week","weight":0.0188},{"period":"1month","weight":0.0257},{"period":"3month","weight":0.0354},{"period":"6month","weight":0.1575},{"period":"1year","weight":0.1664},{"period":"ytd","weight":0.1826}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"申联生物医药(上海)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"12388人(较上一季度增加30.87%)","perCapita":"33148股","listingDate":"2019-10-28","address":"上海市闵行区江川东路48号","registeredCapital":"41064万元","survey":" 申联生物医药(上海)股份有限公司的主营业务是涵盖动物预防、治疗及诊断生物产品的研发、生产和销售。公司的主要产品是系列猪、牛羊口蹄疫疫苗、猪圆环病毒2型亚单位疫苗、牛结节性皮肤病灭活疫苗及系列兽医诊断制品。公司于2024年荣获第七届中国(上海)国际发明创新展览会金奖2项。","listedPrice":8.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"申联生物(688098)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供申联生物(688098)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"申联生物,688098,申联生物股票,申联生物股票老虎,申联生物股票老虎国际,申联生物行情,申联生物股票行情,申联生物股价,申联生物股市,申联生物股票价格,申联生物股票交易,申联生物股票购买,申联生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"申联生物(688098)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供申联生物(688098)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}